Ubs Group Ag Galapagos Nv Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Galapagos Nv stock. As of the latest transaction made, Ubs Group Ag holds 238,524 shares of GLPG stock, worth $8.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

238,524

Previous 109,011 118.81%

Holding current value

$8.23 Million

Previous $2.74 Million 143.83%

% of portfolio

0.0%

Previous 0.0%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$23.04 - $29.2 $2.98 Million - $3.78 Million	129,513 Added 118.81%	238,524 $6.68 Million
Q1 2025 May 13, 2025	BUY	$22.69 - $28.79 $758,572 - $962,507	33,432 Added 44.23%	109,011 $2.74 Million
Q4 2024 Feb 14, 2025	BUY	$25.22 - $31.05 $1.88 Million - $2.32 Million	74,597 Added 7596.44%	75,579 $2.08 Million
Q3 2024 Nov 14, 2024	SELL	$24.2 - $30.67 $1,790 - $2,269	-74 Reduced 7.01%	982 $28,000
Q2 2024 Aug 13, 2024	SELL	$24.78 - $32.48 $7,954 - $10,426	-321 Reduced 23.31%	1,056 $26,000
Q1 2024 May 13, 2024	SELL	$32.2 - $42.44 $18,740 - $24,700	-582 Reduced 29.71%	1,377 $44,000
Q4 2023 Feb 09, 2024	BUY	$31.87 - $40.71 $40,793 - $52,108	1,280 Added 188.51%	1,959 $79,000
Q3 2023 Nov 09, 2023	SELL	$34.17 - $42.98 $21,219 - $26,690	-621 Reduced 47.77%	679 $23,000
Q2 2023 Aug 11, 2023	BUY	$37.4 - $44.52 $19,784 - $23,551	529 Added 68.61%	1,300 $52,000
Q1 2023 May 12, 2023	SELL	$36.5 - $48.0 $103,368 - $135,936	-2,832 Reduced 78.6%	771 $29,000
Q4 2022 Feb 08, 2023	BUY	$37.44 - $46.51 $78,399 - $97,391	2,094 Added 138.77%	3,603 $159,000
Q3 2022 Nov 10, 2022	BUY	$42.27 - $57.6 $23,544 - $32,083	557 Added 58.51%	1,509 $64,000
Q2 2022 Aug 10, 2022	BUY	$52.3 - $71.59 $7,635 - $10,452	146 Added 18.11%	952 $53,000
Q1 2022 May 16, 2022	SELL	$51.32 - $68.5 $3.36 Million - $4.48 Million	-65,396 Reduced 98.78%	806 $50,000
Q4 2021 Feb 14, 2022	BUY	$47.03 - $57.12 $3.07 Million - $3.73 Million	65,334 Added 7526.96%	66,202 $3.65 Million
Q3 2021 Nov 15, 2021	SELL	$52.17 - $70.2 $67,664 - $91,049	-1,297 Reduced 59.91%	868 $45,000
Q2 2021 Aug 13, 2021	BUY	$68.86 - $83.34 $84,835 - $102,674	1,232 Added 132.05%	2,165 $150,000
Q1 2021 May 12, 2021	SELL	$76.15 - $111.94 $62,214 - $91,454	-817 Reduced 46.69%	933 $71,000
Q4 2020 Feb 11, 2021	BUY	$96.85 - $148.25 $102,370 - $156,700	1,057 Added 152.53%	1,750 $173,000
Q3 2020 Nov 12, 2020	SELL	$122.47 - $213.56 $84,749 - $147,783	-692 Reduced 49.96%	693 $99,000
Q2 2020 Jul 31, 2020	BUY	$185.52 - $231.25 $137,655 - $171,587	742 Added 115.4%	1,385 $273,000
Q1 2020 May 01, 2020	SELL	$143.0 - $274.03 $17,303 - $33,157	-121 Reduced 15.84%	643 $126,000
Q4 2019 Feb 14, 2020	SELL	$146.12 - $215.82 $336,514 - $497,033	-2,303 Reduced 75.09%	764 $158,000
Q3 2019 Nov 14, 2019	BUY	$130.44 - $187.64 $49,567 - $71,303	380 Added 14.14%	3,067 $468,000
Q2 2019 Aug 14, 2019	SELL	$111.45 - $128.93 $45,248 - $52,345	-406 Reduced 13.13%	2,687 $346,000
Q1 2019 May 14, 2019	BUY	$89.61 - $117.78 $141,852 - $186,445	1,583 Added 104.83%	3,093 $364,000
Q4 2018 Feb 14, 2019	SELL	$87.81 - $110.65 $11,151 - $14,052	-127 Reduced 7.76%	1,510 $139,000
Q3 2018 Nov 14, 2018	SELL	$90.63 - $120.22 $28,367 - $37,628	-313 Reduced 16.05%	1,637 $184,000
Q2 2018 Aug 14, 2018	BUY	$88.4 - $105.34 $66,123 - $78,794	748 Added 62.23%	1,950 $180,000
Q1 2018 May 15, 2018	SELL	$94.51 - $120.23 $37,331 - $47,490	-395 Reduced 24.73%	1,202 $120,000
Q4 2017 Feb 14, 2018	BUY	$84.48 - $104.02 $37,762 - $46,496	447 Added 38.87%	1,597 $150,000
Q3 2017 Nov 14, 2017	SELL	$73.17 - $103.47 $89,779 - $126,957	-1,227 Reduced 51.62%	1,150 $117,000
Q2 2017 Aug 14, 2017	SELL	N/A	-1,145 Reduced 32.51%	2,377 $182,000
Q1 2017 Nov 14, 2017	BUY	N/A	3,522	3,522 $303,000

Others Institutions Holding GLPG

# of Institutions

Shares Held

14.1M

Call Options Held

920K

Put Options Held

540K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $2.27B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account